The use of metformin in the treatment of prediabetes

Lidia Witek; Irina Kowalska

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

5/2018
vol. 4

Send email

Copy url:

abstract:

Review paper

The use of metformin in the treatment of prediabetes

Lidia Witek

,

Irina Kowalska

Online publish date: 2018/11/30

View full text Get citation

The term ‘prediabetes’ refers to impaired fasting glucose and impaired glucose tolerance, defined as increased plasma glucose 2 h after an oral glucose tolerance test. People with this disorder have an increased risk of developing type 2 diabetes. According to the recommendations of Diabetes Poland, patients with prediabetes should be offered lifestyle modification and pharmacotherapy with the use of metformin for persons at high risk of diabetes. This drug reduces insulin resistance in liver and skeletal muscle. In the Diabetes Prevention Program metformin slowed down the progression of prediabetes to type 2 diabetes. Metformin has been in use for many years, it is cheap, safe, and does not cause hypoglycaemia.

keywords:

The use of metformin in the treatment of prediabetes

Lidia Witek , Irina Kowalska

prediabetes, impaired fasting glucose, impaired glucose tolerance, metformin, DPP

Lidia Witek

,

Irina Kowalska